Baidu
map

JACC:有卒中风险的房颤患者——阿司匹林 vs 口服抗凝药

2016-06-27 fsy 译 MedSci原创

在中度至重度卒中风险的房颤(AF)患者中,医生建议口服抗凝药物(OAC),而不是阿司匹林。本研究旨在在现实世界心脏病学实践中,在中度至重度卒中风险的AF患者中,探讨与OAC相比,单独阿司匹林处方相关的患者和实践层面的因素。作者确定了2个AF门诊患者队列,这些患者具有中等至高风险血栓栓塞(CHADS2评分≥2和CHA2DS2-VASC≥2),这些患者在2008年和2012年被纳入PINNACLE注册

在中度至重度卒中风险的房颤(AF)患者中,医生建议口服抗凝药物(OAC),而不是阿司匹林。

本研究旨在在现实世界心脏病学实践中,在有中度至重度卒中风险的AF患者中,探讨与OAC相比,单独阿司匹林处方相关的患者和实践层面的因素。

作者确定了2个AF门诊患者队列,这些患者具有中等至高风险血栓栓塞(CHADS2评分≥2和CHA2DS2-VASC≥2),这些患者在2008年和2012年被纳入PINNACLE注册中。研究人员采用调整了患者和临床特点的泊松回归模型,研究了在具有卒中风险的AF患者中,单独阿司匹林 vs OAC处方的患病率和预测因素。

在210380例CHADS2评分≥2的鉴定为抗血栓治疗的患者中,80371(38.2%)例患者使用单独阿司匹林治疗,130009(61.8%)例患者使用华法林或非维生素K拮抗剂OACs治疗。在294642例CHA2DS2-VASC≥2的患者队列中,118398(40.2%)例患者使用单独阿司匹林治疗,176244(59.8%)例患者使用华法林或非维生素K拮抗剂OACs治疗。经过多变量的调整后,高血压、血脂异常、冠心病、心肌梗死病史、不稳定和稳定型心绞痛、近期冠状动脉旁路移植术,以及外周动脉疾病与单独阿司匹林处方相关,然而男性、较高的BMI、卒中史/短暂性缺血发作、全身性栓塞史和充血性心脏衰竭与更频繁的OAC处方相关联。

在有中度至重度卒中高危风险AF人群的一项大的,现实世界的心脏门诊队列研究中,超过1/3的患者单独使用阿司匹林治疗。具体病人的特点预测,阿司匹林处方治疗多于OAC处方。

原始出处:

Jonathan C. Hsu,Thomas M. Maddox,Kevin Kennedy,et al.Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke,JACC,2016.6.27

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853540, encodeId=01ac1853540e0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Nov 01 17:54:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281218, encodeId=9e0f1281218d7, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325256, encodeId=80511325256f3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377371, encodeId=626713e73718f, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614307, encodeId=5f55161430e02, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91426, encodeId=b60691426d6, content=学习了 真不错 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f861634573, createdName=tiantian569, createdTime=Tue Jun 28 11:35:00 CST 2016, time=2016-06-28, status=1, ipAttribution=)]
    2016-11-01 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853540, encodeId=01ac1853540e0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Nov 01 17:54:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281218, encodeId=9e0f1281218d7, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325256, encodeId=80511325256f3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377371, encodeId=626713e73718f, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614307, encodeId=5f55161430e02, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91426, encodeId=b60691426d6, content=学习了 真不错 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f861634573, createdName=tiantian569, createdTime=Tue Jun 28 11:35:00 CST 2016, time=2016-06-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853540, encodeId=01ac1853540e0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Nov 01 17:54:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281218, encodeId=9e0f1281218d7, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325256, encodeId=80511325256f3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377371, encodeId=626713e73718f, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614307, encodeId=5f55161430e02, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91426, encodeId=b60691426d6, content=学习了 真不错 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f861634573, createdName=tiantian569, createdTime=Tue Jun 28 11:35:00 CST 2016, time=2016-06-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853540, encodeId=01ac1853540e0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Nov 01 17:54:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281218, encodeId=9e0f1281218d7, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325256, encodeId=80511325256f3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377371, encodeId=626713e73718f, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614307, encodeId=5f55161430e02, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91426, encodeId=b60691426d6, content=学习了 真不错 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f861634573, createdName=tiantian569, createdTime=Tue Jun 28 11:35:00 CST 2016, time=2016-06-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853540, encodeId=01ac1853540e0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Nov 01 17:54:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281218, encodeId=9e0f1281218d7, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325256, encodeId=80511325256f3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377371, encodeId=626713e73718f, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614307, encodeId=5f55161430e02, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91426, encodeId=b60691426d6, content=学习了 真不错 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f861634573, createdName=tiantian569, createdTime=Tue Jun 28 11:35:00 CST 2016, time=2016-06-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1853540, encodeId=01ac1853540e0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Nov 01 17:54:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281218, encodeId=9e0f1281218d7, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325256, encodeId=80511325256f3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377371, encodeId=626713e73718f, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614307, encodeId=5f55161430e02, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 29 12:54:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91426, encodeId=b60691426d6, content=学习了 真不错 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9f861634573, createdName=tiantian569, createdTime=Tue Jun 28 11:35:00 CST 2016, time=2016-06-28, status=1, ipAttribution=)]
    2016-06-28 tiantian569

    学习了 真不错

    0

相关资讯

Stroke:中年期心肺功能越好,老年时卒中风险越低

近期发表在Stroke的研究表明,45-50岁具有高心肺适能的人群,其65岁后的卒中风险最高可下降37%,并且独立于其他传统的卒中危险因素。德克萨斯大学西南医学中心的Ambarish Pandey博士对1999-2009年纳入的19815名基线年龄在45到50年人群(男性占79%,白人占90%)进行了研究。该研究测量了参与者跑步机上的心肺运动能力,根据心肺能力的高、中、低水平进行分层,并对年龄和性

J Stroke Cerebrovasc Dis: COX1和COX2基因变异与卒中患者阿司匹林抵抗相关

背景:环氧合酶(COX)遗传变异和阿司匹林抵抗(AR)是否相关,结果尚不一致。本研究的目的是调查Cox遗传变异与急性缺血性脑卒中(IS)患者AR的相互作用。方法:研究者招募了850例急性IS患者。阿司匹林治疗7-10天,检测血小板聚集活性。质谱检测CO X基因的四种变异。应用广义多因子降维法(GMDR)分析基因的联合作用。结果:在850例的急性IS患者中,175(20.6%)例患者存在AR,45(

J Neurol Neurosurg Psychiatry: 卒中后早期评估和筛查吞咽困难,减少卒中相关肺炎的发生

背景:没有强有力的证据表明,筛选急性卒中吞咽困难的患者降低卒中相关性肺炎(AIS)的风险,也没有证据表明,入院后什么时候进行筛选。研究者旨在确定延迟床边吞咽困难筛查,且延迟言语和语言治疗师(SALT)对综合性吞咽困难进行评估是否与患者发生SAP的风险相关。方法:这项全国范围内,以登记为基础的,前瞻性队列研究的受试者为英格兰和威尔士的急性卒中患者。在承认在的急性中风。校正患者变量和卒中的严重程度,多

ADA 2016:吡格列酮可降低伴卒中史的前驱糖尿病患者的糖尿病风险

美国糖尿病协会科学年会称,PPAR激动剂吡格列酮可减少2型糖尿病风险,尤其是前驱糖尿病或/和有卒中史的患者。耶鲁的糖尿病中心主任Silvio E. Inzucchi博士和同事对3,876人没有糖尿病、有胰岛素抵抗的患者进行了研究,所有患者近期有卒中或心脏病发作史。患者被随机分为Actos(吡格列酮, Takeda; n = 1,939)或安慰剂组(n = 1,937)。研究人员试图确定匹格列酮对血

Neurology:成人卒中识别量表不适用于儿童

目的:评估辛辛那提院前卒中量表(CPSS)和急诊室卒中识别(ROSIER)工具对急诊科(ED)儿童脑发作的症状的区分情况。方法:回顾性的应用ROSIER和CPSS工具评估2003到2010间的101个卒中儿童,并且从2009到2010年,前瞻性的应用于279例对照组儿童。CPSS阳性为≥1阳性体征(面/不对称的肢体无力、言语障碍),ROSIER阳性为得分≥1。评估这两种工具和患者真实状态之间的准确

Atherosclerosis:血钙水平与心血管疾病发生的风险相关

背景:以前的流行病学研究显示血清钙浓度和心血管疾病(CV)的风险之呈正相关关系,心血管疾病的定义不同,结果也不相同不同的。研究者在瑞典AMORIS队列,检测循环中钙与致命性心血管疾病,心肌梗死(MI)和卒中发生的相关性。方法:研究包括AMORIS数据库中441738个受试者,这项数据库包括随访过程中死亡率和发病率的信息。应用比色法完全自动化的测定总钙浓度;在1985和1995之间,应用溴甲酚绿法测

Baidu
map
Baidu
map
Baidu
map